Is it dangerous to stop hormone therapy, and is there a right age to come off it?

No guideline mandates stopping at a particular age or duration - continuing is meant to be an active, periodically reviewed decision, not an automatic cutoff.

One large registry study found that in the first year after stopping hormone therapy, cardiac and stroke death rates were elevated compared with the background population, especially in women who stopped before 60, though risk fell back to background levels after that first year. This finding is registry-based and cannot fully separate the effect of stopping from the reason a woman stopped in the first place, so it should raise questions about routine forced discontinuation rather than serve as proof that stopping itself is dangerous.

What to know about this answer

The disagreement is over how to interpret an elevated-risk signal right after stopping. Guidelines treat continuation as an individualized, periodically reviewed decision with no mandated stop date. Some field clinicians argue there is no biological reason for routine discontinuation in a woman doing well, and that the registry data actively argue against old 'annual discontinuation trial' habits.

What the research shows, and which source each finding rests on

Finnish national registry (332,202 women): in the first year after discontinuing hormone therapy, standardized cardiac death risk was elevated (SMR 1.26), and stroke death more so (1.63); women who stopped before age 60 had cardiac mortality risk 1.94 versus the background population; beyond the first year, risks fell below background.

D [1]

Fracture and bone protection are not permanent: in WHI extended follow-up, most risks and benefits dissipated after stopping therapy.

B [2]

NAMS 2022 supports longer durations for documented indications, with shared decision-making and periodic reevaluation of benefits and risks.

A [3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Individualize, with periodic review, no mandated stop

guidelines including NAMS 2022

NAMS frames longer duration as appropriate for documented ongoing indications, with shared decision-making and periodic reevaluation - nothing mandates stopping at 5 years or age 60, but continuing is meant to be an active decision, not a default.

A [3]

No routine reason to stop in a woman doing well

field clinicians, strongest in Dr. Felice Gersh, echoed by Dr. Corinne Menn, Dr. Kelly Casperson, and Dr. Vonda Wright

Stopping means losing bone protection, and per the Finnish registry data, the year after stopping shows elevated cardiac and stroke death, especially under 60, which specifically undercuts the old practice of routine 'annual discontinuation trials.'

D [1]B [2]

What would settle it: Randomized discontinuation trials in long-term users (none currently exist), or better registry designs that can separate the reason a woman stopped from the effect of stopping itself.

What is really going on here

Discontinuation-mortality data do not prove that stopping kills - could a recommendation to stop be driven by a new diagnosis that itself raises risk, rather than the stopping itself?
Is there a plan to re-evaluate dose, route, and duration, or only a plan to stop at an arbitrary age?

Questions for your doctor

Is there a specific medical reason I need to stop, or is this a default age-based rule?
If I do stop, what is the plan for my bone and cardiovascular health afterward?
Can we schedule a periodic review of dose and duration instead of a fixed stop date?
If I'm being asked to try a trial period off hormones, what is the reasoning for that specific timing?

Questions with no answer yet

Does the elevated cardiac and stroke death risk seen in the year after stopping hormone therapy reflect a real physiological rebound effect, or mainly reflect that women stop for reasons, such as a new diagnosis or a health scare, that themselves raise short-term death risk?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: This registry finding is vulnerable to exactly this kind of confounding, since standardized mortality ratios against the background population cannot fully separate the effect of stopping from the reason a woman stopped in the first place. No study has been designed to isolate reason-for-stopping from effect-of-stopping.

What would test it: A registry design that captures and adjusts for the documented reason each woman stopped therapy, comparing outcomes in women who stopped for a new safety concern against women who stopped for other reasons such as personal preference or cost.

Would a gradual discontinuation protocol reduce or eliminate the elevated risk seen in the year after stopping, compared with stopping abruptly?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No randomized discontinuation trial exists in long-term hormone therapy users, so nothing is known about whether the way a woman stops, gradually or abruptly, affects this early post-stopping risk pattern.

What would test it: A randomized trial comparing gradual tapering against abrupt discontinuation in long-term users, with cardiovascular outcomes tracked in the year following each approach.

Sources

1.Increased Cardiovascular Mortality Risk in Women Discontinuing Postmenopausal Hormone Therapy.Mikkola TS, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab. 2015;100(12):4588-94. · Comparative or small study
2.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI randomized trials. JAMA. 2013;310(13):1353-68. · Randomised trial
3.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. · Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping